Recently, Robak and colleagues (LYM‐3002) reported significant improvement of PFS, with relative improvement of 59%, by substituting bortezomib (Vc) for vincristine in frontline therapy with R‐CHOP in newly diagnosed MCL patients (n = 487) who were ineligible or not considered for Auto‐HCT 27. Here, DDIT3 is linked to mantle cell lymphoma.